CYP46A1 and Alzheimer disease: Our current results showing unaltered concentrations of free cholesterol in the brain in AD despite reduced expression of CYP46A1 may thus be mediated by a compensatory reduction in de novo cholesterol biosynthesis as suggested by reduced concentrations of lanosterol, the early biosynthetic precursor of cholesterol.